A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial

Clinical and Vaccine Immunology

Volumn 19, Issue 3, 2012, Pages 313-318

  Vajo, Zoltan ^a   Tamas, Ferenc ^b   Jankovicsc, Istvan ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b National Institute of Epidemiology   (Hungary)

^c State Primary Care Center   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTIGENICITY; DRUG DOSE REDUCTION; DRUG SAFETY; ELDERLY CARE; GERIATRIC PATIENT; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SEROCONVERSION; SINGLE DRUG DOSE; VIRION; VIRUS INACTIVATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84857936845     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05619-11     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. 2011. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb. Mortal. Wkly. Rep. 60:1128-1132.
2. Couch RB, et al. 2007. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25:7656-7663. (Pubitemid 47554468)
3. Engler RJ, et al. 2008. Half-vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch. Intern. Med. 168:2405-2414.
4. European Agency for the Evaluation of Medicinal Products. 2007. EMEA/CHMP/BWP/108182/2007:EUrecommendations for the seasonal influenza vaccine composition for the season 2007/2008. European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
5. European Committee for Proprietary Medicinal Products. 1997. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). European Directoriate for the Quality of Medicines and Health Care, Strasbourg, France.
6. European Directoriate for the Quality of Medicines and Health Care. 2007. European pharmacopia, 5.8 CD, 7/2007, p 3406-3407. European Directoriate for the Quality of Medicines and Health Care, Strasbourg, France.
7. European Directoriate for the Quality of Medicines and Health Care. 2005. European pharmacopia, 5.0 01/2005:2053, p 674. European Directoriate for the Quality of Medicines and Health Care, Strasbourg, France.
8. Fazekas G, Martosne-Mendi R, Jankovics I, Szilvasy I, Vajo Z. 2009. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pan- demic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin. Vaccine Immunol. 16:437-443.
9. Frenck RW, Jr, et al. 2011. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 29:5666-5674.
10. Klimov A, Cox N. 2003. Serologic diagnosis of influenza virus infections by hemagglutination inhibition, p 7.1-7.5. Influenza Laboratory Course. Centers for Disease Control and Prevention, Atlanta, GA.
11. Leroux-Roels I, et al. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
12. Palache AM, et al. 1993. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 11:892-908. (Pubitemid 23218795)
13. Treanor J, et al. 2002. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 20:1099-1105. (Pubitemid 34135945)
14. Vajo Z, Tamas F, Sinka L, Jankovics I. 2010. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 375:49-55.
15. Vajo Z, et al. 2010. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J. Virol. 84:1237-1242.
16. Vajo Z, et al. 2008. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr. Infect. Dis. J. 27:1052-1056.
17. Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I. 2007. Inactivated whole virus influenza A (H5N1) vaccine. Emerg. Infect. Dis. 13:807-808. (Pubitemid 46698765)
18. Vajo Z. 2009. Influenza A (H5N1) pandemic prototype vaccine Fluval. Expert Rev. Vaccines 8:619-624.
19. Vajo Z, et al. 2008. Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval-a useful approach to pandemic vaccine development even in less well developed countries? Influenza Other Respir. Viruses 2:211-218.
20. Voordouw AC, et al. 2004. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 292:2089-2095. (Pubitemid 39435099)
21. WHO. 2005. Recommendations for the production and control of influenza vaccines (inactivated). World Health Organ. Tech. Rep. Ser. 927:103.
22. Wood JM, Schild GC, Newman RW, Seagroatt V. 1977. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5:237-247. (Pubitemid 8143405)